Stockscreener 앱 받기
1.13
6.60%
0.07
시간 외 거래:
1.10
-0.03
-2.65%
Actinium Pharmaceuticals Inc 주식(ATNM)의 최신 뉴스
Next Generation Antibody Therapeutics Market, 2nd Edition: Global Industry Trends and Forecast to 2035 | Immunocytokines and Combination Therapies Drive Growth - GlobeNewswire Inc.
Actinium Pharmaceuticals (ATNM) Slips 3.28% to $1.18 as Shares Test Mid-Range SupportFibonacci Fan - siam.in
Actinium Pharmaceuticals, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference - Eastern Progress
ATNM: Initiating Coverage – Diversified Nuclear Medicine Portfolio - finance.yahoo.com
Actinium CEO to present at H.C. Wainwright Glob... - Pluang
Actinium Pharmaceuticals, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference - PR Newswire
Actinium Pharmaceuticals (ATNM) grants director new stock awards - Stock Titan
Actinium Pharmaceuticals (ATNM) grants director $1.00 options and RSUs - stocktitan.net
Actinium (ATNM) Update: Slides 1.79% to $1.10 in Latest Trading; Next Test: Traders Can Monitor the $1.04-$1.16 Range in the Latest SessionBreakout Confirmation - vinanet.vn
Actinium (ATNM) Chart: Ends Up by 3.24% at $1.11 in Latest Trading; Level Watch: the Supplied Trading Band Runs From $1.05 to $1.17Up Down Ratio - vinanet.vn
KPTI Stock Price and Chart — NASDAQ:KPTI - TradingView
ETFs Investing in Actinium Pharmaceuticals, Inc. Stocks - TradingView
Analysts Are Bullish on Top Healthcare Stocks: BridgeBio Pharma (BBIO), Pyxis Oncology (PYXS) - The Globe and Mail
Form 8K Actinium Pharmaceuticals Inc For: 14 August By Investing.com - Investing.com Nigeria
Actinium Pharmaceuticals Announces Actimab-A Intellectual Property And Manufacturing Advances And Provides NYSE American Listing Update - TradingView
Form 8K Actinium Pharmaceuticals Inc For: 14 August By Investing.com - Investing.com India
Form 8K Actinium Pharmaceuticals Inc For: 14 August By Investing.com - Investing.com Canada
Actinium Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update - PR Newswire
Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update - finance.yahoo.com
Actinium Pharmaceuticals (ATNM) Slips 3.4% to $0.77 as Key Support at $0.73 Comes into FocusRelative Volume - vinanet.vn
Actinium Pharmaceuticals (ATNM) Institutional Ownership 2026 - MarketBeat
Actinium Pharmaceuticals (ATNM) Falls 7.5% to $0.75 as Selling Pressure IntensifiesGrowth ETF - dars.gov.et
Levi & Korsinsky Notifies Actinium Pharmaceuticals, Inc. (ATNM) InvestorsLead Plaintiff Deadline on May 27, 2025 - The National Law Review
Actinium Pharmaceuticals, Inc. (Delaware) Revenue Breakdown – AMEX:ATNM - TradingView
Actinium Pharmaceuticals (ATNM) Hovers Near Support With Modest DeclineBullish Pattern Stocks - vinanet.vn
Class Action Lawsuit Filed: Actinium Pharmaceuticals, Inc. (ATNM)Join by May 27, 2025Contact Levi & Korsinsky - The National Law Review
Actinium Pharmaceuticals Inc (ATNM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Did You Lose Money on Actinium Pharmaceuticals, Inc. (ATNM)? Levi - The National Law Review
ATNM|Actinium Pharmaceuticals Inc|Price:0.860|Chg%:-0.024 - TradingKey
TradingKey - TradingKey
Actinium Pharmaceuticals Inc (ATNM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Actinium Pharmaceuticals (ATNM) Q3 2025 earnings summary - Quartr
Actinium Pharmaceuticals (ATNM) Life Sciences Investor Forum Summary - Quartr
Actinium Pharmaceuticals (ATNM) Dips 2.9% as Biotech Stock Nears Support ZoneVWAP Breakout - dars.gov.et
Actinium Pharmaceuticals (ATNM) Dips 2.9% as Biotech Stock Nears Support ZoneSchiff Line - vinanet.vn
Actinium Pharmaceuticals (ATNM) Gains 2.77% as Stock Tests Key Resistance Near $0.97Volume Rate Change - vinanet.vn
Actinium Pharmaceuticals (ATNM) Investor presentation Summary - Quartr
Actinium Pharmaceuticals (ATNM) Proxy Filing Summary - Quartr
Actinium Pharmaceuticals (ATNM) Q3 2025 earnings summary - Quartr
Actinium Pharmaceuticals (ATNM) Q4 2025 earnings summary - Quartr
Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Models - AOL.com
Actinium Company Profile & Introduction - Moomoo
ATNMActinium Pharmaceuticals Inc Earnings - Finviz
Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) - The National Law Review
ATNMActinium Pharmaceuticals Inc Latest SEC Filings - Finviz
Actinium Pharmaceuticals (ATNM) Stages Recovery Attempt Near Critical Support LevelLong Short Pair - dars.gov.et
ATNM Stockholders Have Opportunity to Lead Actinium Pharmaceutica - The National Law Review
ATNM LAWSUIT ALERT: Levi & Korsinsky Notifies Actinium Pharmaceut - The National Law Review
Lost Money on Actinium Pharmaceuticals, Inc. (ATNM)? Urged to Joi - The National Law Review
4.22%
자본화:
|
볼륨(24시간):